Zadno Reza 4

What Happened

• Zadno Reza, a director of Mobia Medical, received two derivative awards (stock options) on July 14, 2026: 19,150 shares and 16,260 shares, for a total of 35,410 share-equivalents. Each grant is reported at $0.00 acquisition price on the Form 4 and is recorded as a derivative award (not an open-market purchase or sale).
• These are compensation awards (routine director equity grants), not sales. The filing was submitted on July 16, 2026, covering the July 14 transactions.

Key Details

• Transaction date: July 14, 2026; Form 4 filed: July 16, 2026.
• Grants: 19,150 shares @ $0.00 and 16,260 shares @ $0.00 (total 35,410); reported as derivative awards.
• Shares owned after transaction: not disclosed in the Form 4.
• Footnotes:
  • F1: The 19,150-share option vests in three substantially equal installments on the first three anniversaries of the grant date.
  • F2: The 16,260-share option will fully vest at the 2027 Annual Meeting per the Non-Employee Director Compensation Policy.
• Filing timeliness: Form 4 was filed two days after the transactions (July 14 → July 16); not indicated as late in the filing.

Context

• These awards are part of typical director compensation. As derivative/option grants, they become exercisable or transferable only according to the vesting schedules noted in the footnotes.
• Because no shares were purchased or sold and no cash changed hands at grant, this report does not reflect immediate economic exposure; future exercise or sale would be reported separately.